RecruitingNCT04207580
A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.
Studying Idiopathic nephrotic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Limoges
- Principal Investigator
- Vincent Guigonis, MDUniversity Hospital, Limoges
- Intervention
- Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome,(other)
- Enrollment
- 1180 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2048
Study locations (30)
- CH d'Agen, Agen, France
- CHU d'Amiens, Amiens, France
- CHU d'Auxerre, Auxerre, France
- CH de la côte basque, Bayonne, France
- CHU de Besançon, Besançon, France
- CHU de Boredeaux, Bordeaux, France
- CHU de Brest, Brest, France
- HCL Lyon, Bron, France
- CH de Chambéry, Chambéry, France
- CHU de Clermont Ferrand, Clermont-Ferrand, France
- CHU de Dijon, Dijon, France
- CH du Val d'Ariège, Foix, France
- CH de la Rochelle, La Rochelle, France
- CHU de Grenoble, La Tronche, France
- CH de Versaille, Le Chesnay, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04207580 on ClinicalTrials.govOther trials for Idiopathic nephrotic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06820866Non-invasive Diagnosis of Idiopathic Nephrotic SyndromesAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGPHASE3NCT05627557A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic SyndromeHoffmann-La Roche